Chronic Myelomonocytic Leukemia: A Giving Smarter Guide
Poor treatment options. No Cure. Patients and families affected by chronic myelomonocytic leukemia (CMML) face many challenges and critical unmet needs, issues mirrored by the current state of the disease’s research. On a societal scale, the economic burden of leukemia is immense. At the time of this report, Leukemia’s cost was estimated at $5.44 billion annually, and projected to increase by 25 percent over the next 10 years.
In this Giving Smarter Guide, the Milken Institute Center for Strategic Philanthropy outlines the key barriers to CMML research progress that impede treatments, and presents recommendations of how strategic philanthropic investments can change the trajectory of research and ultimately benefit CMML patients.